Trials / Active Not Recruiting
Active Not RecruitingNCT06099704
Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
A Prospective, Observational Study of Canadian Patients Receiving Dupixent® for Moderate to Severe Atopic Dermatitis
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 305 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, 18-month observational study of adult, adolescent and pediatric Canadian participants with Atopic Dermatitis (AD) commonly known as Eczema, who receive treatment with Dupixent for moderate-to-severe AD (msAD) according to the Canadian-specific prescribing information (in accordance with the Canadian Dupixent Product Monograph). The study will be conducted in approximately 30 centers in Canada to assess participants of all ethnicities and races. At each participating site, all AD participants who receive an initial prescription for Dupixent will be invited to participate in this study, until the Canadian enrollment goal is achieved.
Detailed description
The duration of the study for each participant will be of 18 months.
Conditions
Timeline
- Start date
- 2023-10-10
- Primary completion
- 2026-04-10
- Completion
- 2026-04-10
- First posted
- 2023-10-25
- Last updated
- 2025-03-18
Locations
29 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT06099704. Inclusion in this directory is not an endorsement.